Columbia – BridgeBio Alliance
The Columbia-BridgeBio Alliance, administered by Columbia Technology Ventures, is a strategic collaboration aimed at advancing therapeutics development for genetically driven diseases.
Interested faculty should email Sam Galindo ([email protected]) for more information
Program Information
Therapeutics development for genetically driven diseases including:
- Any disease with at least roughly 2,000 patients in the US + EU and with a well-characterized mutation known to cause the disease
- Any approach that directly targets or compensates for the underlying genetic defect (e.g., directly inhibits a gain-of-function protein, replaces a loss-of-function protein)
- Any therapeutic modality that has shown general feasibility in humans, such as by showing efficacy in a phase 2 or phase 3 clinical trial. This generally includes small molecules, antibodies, antibody-drug conjugates, peptides, topical formulas, viral-based gene therapies, and oligonucleotides.
- Earliest stage of project eligible: A new mutation has been identified with evidence it is a driver of disease, and the investigator has a screening assay for drugs that target the mutated protein
- Investigator has identified a lead drug that still needs optimization before consideration as a development candidate
- Investigator has a development candidate that requires funding for IND-enabling studies
- Any novel modalities or combinations of modalities that have not been tested clinically as therapeutic agents before. This includes most types of synthetic nanoparticles like quantum dots and gold nanoparticles, and in some cases combinations of modalities.
- Funding for basic research to identify new mechanisms of disease
- Funding for repurposing approved drugs (unless there is a clear path to novel IP)
- Funding for new diagnostics, digital health, or other life science applications outside of therapeutics
Depending on the stage of the project, projects selected by BridgeBio may receive funding through either:
1) A grant awarded through Sponsored Research Agreement (SRA)
2) SRA funding with IP rights/licensing terms
3) Direct investment into a start-up. Funding mechanism and agreement terms will be negotiated separately on a project-specific basis.
Questions? Please reach out to BridgeBio's Head of Strategic Alliances, Eric Gomez, at [email protected].
About BridgeBio
BridgeBio Pharma, Inc. (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company’s first two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow on LinkedIn and Twitter.